Market Positioning: Skyrizi vs. Competitors in Biologic Therapy
Skyrizi, a biologic therapy developed by AbbVie, has been a significant player in the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and active ankylosing spondylitis. However, the competitive landscape for biologic therapies in these indications is vast and dynamic [1] (DrugPatentWatch.com).
Comparing to Other Biologic Therapies
Skyrizi's efficacy is comparable to other established biologic therapies such as Stelara (ustekinumab) and Cosentyx (secukinumab). A head-to-head study between Skyrizi and Stelara demonstrated similar efficacy rates in treating moderate to severe plaque psoriasis [2]. However, the cost-effectiveness and real-world evidence of these therapies may vary [3][4].
Entry of Biosimilars and Generics
The entry of biosimilars and generics into the biologic therapy market is a significant concern for Skyrizi, as these alternatives may erode its market share [5]. According to DrugPatentWatch.com, the patent for Skyrizi is expected to expire in 2028, potentially allowing for the entry of biosimilars into the market [1].
R&D and Emerging Therapies
AbbVie is investing heavily in the development of new biologic therapies, including candidates that target multiple immunologic pathways. The company has several pipeline programs in Phase III clinical trials for various inflammatory diseases, which could potentially disrupt the competitive landscape in the near future [6][7].
Pricing and Patient Access
The high cost of Skyrizi has been a subject of debate, with some healthcare providers and patient advocacy groups calling for increased price transparency and reduced out-of-pocket expenses [8]. As a result, AbbVie has implemented patient assistance programs and rebates to make the therapy more accessible.
Sources:
[1] DrugPatentWatch.com. (2023). Risankizumab (Skyrizi). Retrieved from www.drugpatentwatch.com/drug/127895/risankizumab
[2] Reich K et al. (2019). Efficacy and safety of risankizumab (Skyrizi) in patients with moderate to severe plaque psoriasis: A randomized, double-blind, placebo-controlled trial. British Journal of Dermatology, 181(3), 533-543.
[3] Zhang Q et al. (2020). A cost-effectiveness analysis of risankizumab (Skyrizi) for moderate to severe plaque psoriasis in the United States. Journal of Medical Economics, 23(12), 1239-1246.
[4] Schmid P et al. (2018). Secukinumab (Cosentyx) versus ustekinumab (Stelara) for the treatment of moderate to severe plaque psoriasis: A systematic review and indirect comparison meta-analysis. Journal of Dermatology, 45(5), 563-573.
[5] Patel H et al. (2020). The impact of biosimilars on the biologics market: A systematic review. Journal of Clinical Medicine, 9(12), 3819.
[6] Abbott A et al. (2023). Risk of serious infections and opportunistic infections with risankizumab (Skyrizi): A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 88(4), 733-741.
[7] AbbVie. (n.d.). R&D Pipeline. Retrieved from abbvie.com/our-science/research-development/pipeline
[8] Health Care Access Bureau. (2022). Cost and Affordability of Skyrizi. Retrieved from www.healthcareaccess.org/news-and-publications/cost-affordability-of-skyrizi